Jason Gerberry
Stock Analyst at B of A Securities
(3.82)
# 751
Out of 4,412 analysts
91
Total ratings
55.32%
Success rate
5.9%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Buy | $82 → $91 | $73.26 | +24.22% | 1 | Apr 17, 2024 | |
| GLPG Galapagos NV | Downgrades: Underperform | $41 → $31 | $28.76 | +7.79% | 5 | Apr 1, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $12 → $11 | $4.72 | +133.05% | 3 | Mar 25, 2024 | |
| CPRX Catalyst Pharmaceuticals | Initiates: Buy | $23 | $14.89 | +54.47% | 1 | Mar 7, 2024 | |
| ALKS Alkermes | Maintains: Neutral | $27 → $29 | $24.68 | +17.50% | 5 | Jan 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $29 → $37 | $22.12 | +67.27% | 2 | Jan 2, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $67 → $80 | $60.72 | +31.75% | 2 | Jan 2, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $52 → $56 | $40.50 | +38.27% | 2 | Jan 2, 2024 | |
| PROK ProKidney | Downgrades: Neutral | $8 → $2 | $2.12 | -5.66% | 1 | Jan 2, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $52 → $62 | $41.59 | +49.07% | 3 | Jan 2, 2024 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Underperform | $30 | $29.32 | +2.32% | 2 | Jan 2, 2024 | |
| BLUE bluebird bio | Maintains: Buy | $12 → $5 | $0.92 | +441.83% | 6 | Dec 21, 2023 | |
| IMVT Immunovant | Maintains: Buy | $49 → $51 | $27.17 | +87.71% | 3 | Dec 21, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Neutral | $63 | $41.11 | +53.25% | 1 | Nov 17, 2023 | |
| VTRS Viatris | Downgrades: Underperform | $9 | $11.57 | -22.21% | 2 | Oct 23, 2023 | |
| TEVA Teva Pharmaceutical | Maintains: Buy | $12 → $13 | $13.81 | -5.87% | 7 | Sep 8, 2023 | |
| OCS Oculis Holding AG | Maintains: Buy | $23 → $24 | $12.02 | +99.67% | 2 | Aug 30, 2023 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $204 → $217 | $109.46 | +98.25% | 3 | Aug 10, 2023 | |
| FGEN FibroGen | Downgrades: Underperform | $4 → $2 | $1.04 | +92.31% | 6 | Aug 8, 2023 | |
| AXSM Axsome Therapeutics | Upgrades: Neutral | $59 → $81 | $71.71 | +12.95% | 2 | Aug 8, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $450 → $500 | $733.51 | -31.83% | 5 | May 24, 2023 | |
| CARA Cara Therapeutics | Maintains: Underperform | $6 → $4 | $0.68 | +484.54% | 2 | May 16, 2023 | |
| ACLX Arcellx | Maintains: Buy | $39 → $50 | $51.92 | -3.70% | 3 | May 10, 2023 | |
| ALLO Allogene Therapeutics | Downgrades: Underperform | $9 | $2.89 | +211.42% | 1 | Dec 12, 2022 | |
| OGN Organon & Co. | Downgrades: Underperform | $37 → $25 | $18.55 | +34.77% | 3 | Oct 14, 2022 | |
| BYSI BeyondSpring | Downgrades: Underperform | n/a | $2.13 | - | 2 | Dec 2, 2021 | |
| BHC Bausch Health Companies | Downgrades: Underperform | n/a | $8.71 | - | 2 | Mar 24, 2021 | |
| CHRS Coherus BioSciences | Initiates: Neutral | n/a | $2.04 | - | 1 | Jul 16, 2020 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Neutral | n/a | $6.87 | - | 1 | Jul 15, 2020 | |
| PFE Pfizer | Maintains: Buy | n/a | $25.40 | - | 2 | Apr 1, 2019 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | n/a | $44.85 | - | 4 | Feb 19, 2019 | |
| ABBV AbbVie | Maintains: Buy | n/a | $159.62 | - | 3 | Oct 4, 2018 | |
| MRK Merck & Co. | Maintains: Buy | n/a | $131.20 | - | 3 | Jul 30, 2018 |
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $82 → $91
Current: $73.26
Upside: +24.22%
Galapagos NV
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.76
Upside: +7.79%
Lyra Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $4.72
Upside: +133.05%
Catalyst Pharmaceuticals
Mar 7, 2024
Initiates: Buy
Price Target: $23
Current: $14.89
Upside: +54.47%
Alkermes
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $24.68
Upside: +17.50%
Arrowhead Pharmaceuticals
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $22.12
Upside: +67.27%
Vaxcyte
Jan 2, 2024
Maintains: Buy
Price Target: $67 → $80
Current: $60.72
Upside: +31.75%
Xenon Pharmaceuticals
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $40.50
Upside: +38.27%
ProKidney
Jan 2, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $2.12
Upside: -5.66%
Ionis Pharmaceuticals
Jan 2, 2024
Upgrades: Buy
Price Target: $52 → $62
Current: $41.59
Upside: +49.07%
Harmony Biosciences Holdings
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $29.32
Upside: +2.32%
bluebird bio
Dec 21, 2023
Maintains: Buy
Price Target: $12 → $5
Current: $0.92
Upside: +441.83%
Immunovant
Dec 21, 2023
Maintains: Buy
Price Target: $49 → $51
Current: $27.17
Upside: +87.71%
Amphastar Pharmaceuticals
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $41.11
Upside: +53.25%
Viatris
Oct 23, 2023
Downgrades: Underperform
Price Target: $9
Current: $11.57
Upside: -22.21%
Teva Pharmaceutical
Sep 8, 2023
Maintains: Buy
Price Target: $12 → $13
Current: $13.81
Upside: -5.87%
Oculis Holding AG
Aug 30, 2023
Maintains: Buy
Price Target: $23 → $24
Current: $12.02
Upside: +99.67%
Jazz Pharmaceuticals
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $109.46
Upside: +98.25%
FibroGen
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $1.04
Upside: +92.31%
Axsome Therapeutics
Aug 8, 2023
Upgrades: Neutral
Price Target: $59 → $81
Current: $71.71
Upside: +12.95%
Eli Lilly
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $733.51
Upside: -31.83%
Cara Therapeutics
May 16, 2023
Maintains: Underperform
Price Target: $6 → $4
Current: $0.68
Upside: +484.54%
Arcellx
May 10, 2023
Maintains: Buy
Price Target: $39 → $50
Current: $51.92
Upside: -3.70%
Allogene Therapeutics
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.89
Upside: +211.42%
Organon & Co.
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $18.55
Upside: +34.77%
BeyondSpring
Dec 2, 2021
Downgrades: Underperform
Price Target: n/a
Current: $2.13
Upside: -
Bausch Health Companies
Mar 24, 2021
Downgrades: Underperform
Price Target: n/a
Current: $8.71
Upside: -
Coherus BioSciences
Jul 16, 2020
Initiates: Neutral
Price Target: n/a
Current: $2.04
Upside: -
Verrica Pharmaceuticals
Jul 15, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.87
Upside: -
Pfizer
Apr 1, 2019
Maintains: Buy
Price Target: n/a
Current: $25.40
Upside: -
Bristol-Myers Squibb Company
Feb 19, 2019
Maintains: Neutral
Price Target: n/a
Current: $44.85
Upside: -
AbbVie
Oct 4, 2018
Maintains: Buy
Price Target: n/a
Current: $159.62
Upside: -
Merck & Co.
Jul 30, 2018
Maintains: Buy
Price Target: n/a
Current: $131.20
Upside: -